Author: Andrew Powrie-Smith Date: 05/04/2016 Version: draft

To support the shared objective of rapid access to the latest effective and life-saving medicines, industry remains committed to engaging with payers on flexible and innovative pricing and funding models

A pioneering patient access scheme between industry and health services for the multiple myeloma treatment bortezomib in the UK saw reimbursement for patients who did not respond after four treatment cycles covered directly by the manufacturer with an average potential saving of GBP 12,198 per non-responsive patient1

Industry is keen to engage in the debate and to partner with payers to deliver outcomes driven sustainable healthcare systems

Industry is keen to engage in the debate and to partner with payers to deliver outcomes driven sustainable healthcare systems

The objective of outcomes-focused healthcare systems is to deliver better patient outcomes at the same or lower cost...
relying on quality outcome data
as starting point to improve care cycle
Value
Patient
Health
information
Medicines
Care
management
Care delivery
MedTech
Outcome
Cost
=
Holistic approach
Feedback
and
learning
Transparent, high-quality
outcomes data
Analyze
variation

Identify
current best
practices
Change behavior
Value
Benefits of a focus on outcomes: improved patient outcomes, reduced variation, reduced medical cost, continuous improvement

Across Europe, governments and the biopharaceutical industry are developing stability agreements that balance access to medicines with support for innovation

Across Europe, governments and the biopharaceutical industry are developing stability agreements that balance access to medicines with support for innovation

Voluntary agreement / Memorandum of understanding
Mandatory clawback
Voluntary agreement under negotiation